

Dongxu Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/993453/publications.pdf>

Version: 2024-02-01

12
papers

461
citations

933447

10
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

541
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Structure and regulation of ZCCHC4 in m6A-methylation of 28S rRNA. <i>Nature Communications</i> , 2019, 10, 5042. | 12.8 | 72 |
| 2 | A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models. <i>Science Translational Medicine</i> , 2021, 13, eabj1578. | 12.4 | 67 |
| 3 | Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation. <i>Journal of the American Chemical Society</i> , 2021, 143, 15073-15083. | 13.7 | 66 |
| 4 | ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. <i>Molecular Cell</i> , 2018, 72, 341-354.e6. | 9.7 | 64 |
| 5 | BAHCC1 binds H3K27me3 via a conserved BAH module to mediate gene silencing and oncogenesis. <i>Nature Genetics</i> , 2020, 52, 1384-1396. | 21.4 | 57 |
| 6 | Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7. <i>Cell Chemical Biology</i> , 2019, 26, 1365-1379.e22. | 5.2 | 38 |
| 7 | A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells. <i>Cell Chemical Biology</i> , 2022, 29, 386-397.e9. | 5.2 | 30 |
| 8 | Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. <i>Oncogene</i> , 2022, 41, 3328-3340. | 5.9 | 18 |
| 9 | Novel RNA-Affinity Proteogenomics Dissects Tumor Heterogeneity for Revealing Personalized Markers in Precision Prognosis of Cancer. <i>Cell Chemical Biology</i> , 2018, 25, 619-633.e5. | 5.2 | 15 |
| 10 | Reprogramming CBX8-PRC1 function with a positive allosteric modulator. <i>Cell Chemical Biology</i> , 2022, 29, 555-571.e11. | 5.2 | 12 |
| 11 | Epstein-Barr virus genomes in Hodgkin's disease and non-Hodgkin's lymphomas. <i>Pathology International</i> , 1995, 45, 735-741. | 1.3 | 11 |
| 12 | DOT1L activity in leukemia cells requires interaction with ubiquitylated H2B that promotes productive nucleosome binding. <i>Cell Reports</i> , 2022, 38, 110369. | 6.4 | 11 |